Metformin and Colorectal Cancer

被引：42
作者：
Higurashi, Takuma [1 ]
Nakajima, Atsushi [1 ]
机构：
[1] Yokohama City Univ, Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan
来源：
FRONTIERS IN ENDOCRINOLOGY | 2018年 / 9卷
基金：
日本学术振兴会;
关键词：
metfromin; colorectal cancer; chemoprevention; epidemiology; basic research; review; clinical trials; ABERRANT CRYPT FOCI; TYPE-2; DIABETES-MELLITUS; REDUCED RISK; COLON-CANCER; DOUBLE-BLIND; PREVENTION; COHORT; MTOR; CHEMOPREVENTION; THERAPY;
D O I：
10.3389/fendo.2018.00622
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Colorectal Cancer (CRC) is one of the most frequently encountered neoplasms in humans. The incidence of CRC has been increasing and new strategies for prevention, including chemoprevention, are required to lower its incidence and associated mortality. Metformin is a biguanide compound commonly used for the treatment of diabetes mellitus. Many recent basic research, epidemiological and clinical trial studies have indicated that metformin has benefits not only in diabetes treatment, but also in lowering the risk of developing cancer (including CRC). These studies indicate that metformin may be a candidate chemoprevention agent for CRC. This review article shall discuss the present evidence of metformin treatment and CRC, as well as outline our challenge in the investigation of metformin use in chemoprevention therapy for colorectal tumors.
引用
收藏
页数：7
相关论文
共 58 条
  • [1] Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
    Alimova, Irina N.
    Liu, Bolin
    Fan, Zeying
    Edgerton, Susan M.
    Dillon, Thomas
    Lind, Stuart E.
    Thor, Ann D.
    [J]. CELL CYCLE, 2009, 8 (06) : 909 - 915
  • [2] Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
    Anisimov, Vladimir N.
    [J]. CURRENT DRUG TARGETS, 2016, 17 (04) : 439 - 446
  • [3] [Anonymous], COL CANC 2011 REP
  • [4] Metformin inhibits development of colon malignant tumors induced by 1,2-dimethylhydrazine in rats
    Bekusova V.V.
    Patsanovskii V.M.
    Nozdrachev A.D.
    Anisimov V.N.
    [J]. Doklady Biological Sciences, 2016, 468 (1) : 97 - 100
  • [5] Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats
    Bekusova, Viktoria V.
    Patsanovskii, Vasily M.
    Nozdrachev, Alexander D.
    Trashkov, Alexandr P.
    Artemenko, Margarita R.
    Anisimov, Vladimir N.
    [J]. CANCER BIOLOGY & MEDICINE, 2017, 14 (01) : 100 - 107
  • [6] The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
    Ben Sahra, I.
    Laurent, K.
    Loubat, A.
    Giorgetti-Peraldi, S.
    Colosetti, P.
    Auberger, P.
    Tanti, J. F.
    Le Marchand-Brustel, Y.
    Bost, F.
    [J]. ONCOGENE, 2008, 27 (25) : 3576 - 3586
  • [7] ROLE OF ABERRANT CRYPT FOCI IN UNDERSTANDING THE PATHOGENESIS OF COLON-CANCER
    BIRD, RP
    [J]. CANCER LETTERS, 1995, 93 (01) : 55 - 71
  • [8] Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case-Control Analysis
    Bodmer, Michael
    Becker, Claudia
    Meier, Christian
    Jick, Susan S.
    Meier, Christoph R.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (02) : 280 - 286
  • [9] A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus
    Bradley, Marie C.
    Ferrara, Assiamira
    Achacoso, Ninah
    Ehrlich, Samantha F.
    Quesenberry, Charles P., Jr.
    Habel, Laurel A.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (05) : 525 - 530
  • [10] Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study
    Cardel, Majken
    Jensen, Sara M.
    Pottegard, Anton
    Jorgensen, Trine L.
    Hallas, Jesper
    [J]. CANCER MEDICINE, 2014, 3 (05): : 1458 - 1465
123456